|
Study Flags Antifungal Resistance Mechanisms in Indian Candida auris Isolates
A Nature Communications study reports Indian Candida auris isolates showing genetic mechanisms that drive antifungal drug resistance. The findings flag multiple biological routes used by fungal pathogens to evade antifungal drugs, with C. auris noted for multidrug resistance in hospital settings.
Candida auris and Antifungal Resistance:
| Dimension | Key Details |
|---|---|
| Antifungal resistance mechanisms | Fungal evasion of antifungals comprises gene mutations, gene amplification, and cellular compensatory mechanisms. |
| Candida auris | Candida auris comprises an emerging yeast species with multidrug resistance. |
| First report of Candida auris | First report of Candida auris comprises 2009 in Japan. |
| Disease profile | Candida auris comprises capability for invasive bloodstream infections and systemic or invasive disease. |
| High-risk setting | Risk settings for Candida auris comprise hospital and intensive care unit (ICU) settings. |
| Mortality range | Reported mortality rates among infected patients comprise 30% to 40%. |
| Clinical management difficulty | Challenges with Candida auris comprise difficult identification and treatment. |
| Fungi | Fungi comprise eukaryotic, non-phototrophic living organisms with rigid cell walls within the fungi kingdom. |
| Fungi (kingdom status) | Fungi comprise a distinct kingdom separate from plants and animals. |
| Main types of fungi | Three main types of fungi comprise mushrooms, molds, and yeasts. |
| Typical fungal environment | Typical fungal environments comprise warm and moist environments. |
| Human body temperature | Historical protection against many fungal species comprises human body temperature of approximately 37°C. |
| Fungal infection-mammalian selection hypothesis | The hypothesis comprises global warming-linked selection of heat-tolerant fungi, increased survival at mammalian body temperatures, and higher potential for human infection. |
| Conventional approach | The conventional approach comprises a cycle of drug targeting, resistance development, stronger drug development, and further resistance. |
| Proposed alternative strategy | The proposed alternative strategy comprises focus on less critical pathways rather than targeting essential survival molecules. |
| Proposed strategy | The proposed alternative strategy comprises reduction of fungal pathogenicity instead of eliminating the fungus entirely, and lower selection pressure with slower evolution of resistance. |